237 related articles for article (PubMed ID: 21816148)
1. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats.
Ran J; Hirano T; Adachi M
Am J Physiol Endocrinol Metab; 2004 Aug; 287(2):E227-32. PubMed ID: 15082419
[TBL] [Abstract][Full Text] [Related]
3. The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview.
Brunner HR
J Hum Hypertens; 2002 May; 16 Suppl 2():S13-6. PubMed ID: 11967728
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
Sada T; Mizuno M
Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):257-69. PubMed ID: 15467259
[TBL] [Abstract][Full Text] [Related]
5. Antagonizing the angiotensin II subtype 1 receptor: a focus on olmesartan medoxomil.
Nussberger J; Koike H
Clin Ther; 2004; 26 Suppl A():A12-20. PubMed ID: 15291375
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.
Koike H; Sada T; Mizuno M
J Hypertens Suppl; 2001 Jun; 19(1):S3-14. PubMed ID: 11451212
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
Mizuno M; Sada T; Kato M; Koike H
Hypertens Res; 2002 Mar; 25(2):271-8. PubMed ID: 12047043
[TBL] [Abstract][Full Text] [Related]
8. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension.
Inada Y; Murakami M; Kaido K; Nakao K
Arzneimittelforschung; 1999 Jan; 49(1):13-21. PubMed ID: 10028373
[TBL] [Abstract][Full Text] [Related]
9. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
Gardner SF; Franks AM
Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
[TBL] [Abstract][Full Text] [Related]
10. Olmesartan medoxomil: an angiotensin II-receptor blocker.
Brousil JA; Burke JM
Clin Ther; 2003 Apr; 25(4):1041-55. PubMed ID: 12809956
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
[TBL] [Abstract][Full Text] [Related]
12. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Nangaku M; Miyata T; Sada T; Mizuno M; Inagi R; Ueda Y; Ishikawa N; Yuzawa H; Koike H; van Ypersele de Strihou C; Kurokawa K
J Am Soc Nephrol; 2003 May; 14(5):1212-22. PubMed ID: 12707391
[TBL] [Abstract][Full Text] [Related]
13. Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats.
Okada K; Hirano T; Ran J; Adachi M
Hypertens Res; 2004 Apr; 27(4):293-9. PubMed ID: 15127887
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
Chrysant SG; Marbury TC; Robinson TD
J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist.
Lee BH; Seo HW; Kwon KJ; Yoo SE; Shin HS
J Cardiovasc Pharmacol; 1999 Mar; 33(3):375-82. PubMed ID: 10069671
[TBL] [Abstract][Full Text] [Related]
17. Chronic angiotensin II inhibition increases levels of calcitonin gene-related peptide mRNA of the dorsal root ganglia in spontaneously hypertensive rats.
Kawasaki H; Inaizumi K; Nakamura A; Hobara N; Kurosaki Y
Hypertens Res; 2003 Mar; 26(3):257-63. PubMed ID: 12675282
[TBL] [Abstract][Full Text] [Related]
18. Comparative cardiovascular effects of the angiotensin II type 1 receptor antagonists ZD 7155 and losartan in the rat.
Junggren IL; Zhao X; Sun X; Hedner T
J Pharm Pharmacol; 1996 Aug; 48(8):829-33. PubMed ID: 8887734
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic profile of TA-606, a novel angiotensin II-receptor antagonist in the rat.
Hashimoto Y; Ohashi R; Kurosawa Y; Minami K; Kaji H; Hayashida K; Narita H; Murata S
J Cardiovasc Pharmacol; 1998 Apr; 31(4):568-75. PubMed ID: 9554806
[TBL] [Abstract][Full Text] [Related]
20. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist.
Yoshida K; Kohzuki M
Cardiovasc Drug Rev; 2004; 22(4):285-308. PubMed ID: 15592575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
